Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study

In this small pilot sub-study, longitudinal gut microbiota composition changes, after successful treatment of hepatitis C virus (HCV) with the co-formulated glecaprevir/pibrentasvir (GLE/PIB), were analyzed before treatment (baseline) and 12 weeks post-treatment. Participating patients provided a fr...

Полное описание

Библиографические подробности

Главные авторы:	Bahtiyar Yilmaz, Lisa Ruckstuhl, Beat Müllhaupt, Lorenzo Magenta, Melanie Harrer Kuster, Olivier Clerc, Ralph Torgler, Nasser Semmo
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2021-09-01
Серии:	Pharmaceuticals
Предметы:	HCV gut microbiota alpha-diversity beta-diversity direct-acting antivirals
Online-ссылка:	https://www.mdpi.com/1424-8247/14/9/931
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!